Pain, Reward, Attention and Neurocircuitry: Biomarkers of Suicidality
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Biomarkers for Suicide Risk
研究概览
简要总结
The ultimate aim of this study is to identify a biomarker of suicide risk in MDD by measuring the "hedonic spectrum" (pain and reward responsivity), attention and its associated brain structures using brain scans (fMRI and DTI), as well as the stability of markers over time.
详细描述
The issue of suicide has continued to puzzle researchers in the field of psychiatry. Edwin Shneidman, a prominent researcher on suicide emphasized "the most evident fact about suicidology and suicidal events is that they are multidimensional...containing concomitant biological, sociological, and psychological (interpersonal and intrapsychic)...elements". Yet, no study to date has attempted to integrate these dimensions when evaluating suicide risk. Considering the presence of a psychiatric illness is a primary predictor of suicide, it is important to develop a unified understanding of risk factors that integrate current clinical and neurobiological findings in this population.
Our aim is to: (1) identify an integrated biomarker model to predict risk of suicide attempt in patients with Major Depressive Disorder (MDD) with and without a history of suicide attempt, using neuroimaging, neurocognitive testing and behavioural tasks, and (2) test the stability of this model using a prospective 1 year design.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •DSM-5 criteria for Major Depressive Episode within a MDD, confirmed through MINI diagnosis104
- •Ages between 18 and 70 years
- •Hamilton Depression Rating Scale - 17 item (HAMD-17) >= 14
- •Capable of giving informed consent
- •Groups 1 and 2 participants only: HAMD-17 item 3 (suicide) >= 2
- •Group 2 participants only: positive history of a suicide attempt within the last six months
- •Group 3 participants only: positive history of a lifetime suicide attempt
排除标准
- •Pregnancy/lactation
- •Medical condition requiring immediate investigation or treatment
- •Recent (< 6 months)/current history of drug abuse/dependence (other than caffeine, or nicotine)
- •Lifetime history of psychosis, Bipolar I or Bipolar II; other Axis I comorbidities are allowable
- •Individuals who are taking a daily sedative hypnotic, atypical antipsychotic or stimulant must be on a stable dose for at least 4 weeks prior to the neuroimaging scan. The dose must not be taken after 10:00pm the evening prior to the scan. Those receiving a benzodiazepine or an atypical antipsychotic on an "as needed" basis (taken, but not every day) will be washed out of their benzodiazepine/atypical antipsychotic for two weeks prior to neuroimaging. Those receive stimulants on an "as needed" basis will be washed out for 1-3 days prior to neuroimaging, depending on the stimulant half-life.
- •Participation in experimental treatment trials for the study duration.
结局指标
主要结局
Biomarkers for Suicide Risk
时间窗: 12 months
Potential biomarkers for suicide risk including brain scans, genomic or proteomic makers,
次要结局
未报告次要终点